💊 VKTX Rises on Phase IIb Data & Acquisition Buzz, ZLAB Teams with Pfizer, TGTX Soars on Deloitte Fast 500 Recognition | Biotech Sector Insights
(IBB) has seen a modest increase of 0.2% since Wednesday. Key contributors to this performance include Amgen Inc. (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Waters Corporation (WAT), and Biogen Inc. (BIIB).
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Thursday, November 21
IBB [+0.2%]
iShares Biotechnology ETF
The iShares Biotechnology ETF (IBB) has seen a modest increase of 0.2% since Wednesday. Key contributors to this performance include Amgen Inc. (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Waters Corporation (WAT), and Biogen Inc. (BIIB). Amgen appointed Howard Chang as Senior Vice President of Research and Chief Scientific Officer, aiming to bolster its research capabilities. Gilead received an upgraded price target from Mizuho analyst Salim Syed, reflecting a positive outlook alongside ongoing collaboration with Hookipa Pharma on a Phase 1b clinical trial for HIV. Additionally, the Russell 2000 Index rose by 1.34%, which may also be influencing the movement of IBB amid broader market trends.